Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Overview of attention for article published in American Journal of Clinical Dermatology, January 2017

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

facebook: 2 Facebook pages

Citations

dimensions_citation: 30 Dimensions

Readers on

mendeley: 70 Mendeley

Summary X Facebook Dimensions citations

So far, Altmetric has seen 2 public wall posts from 2 users.

Probity Medical Research Inc., 15 Sep 2017

PMR #dermatologist Dr. Kim Papp co-authored "Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A…

American Journal of Clinical Dermatology, 15 Jan 2017

Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized…